• HIV-1 infection

• On a suppressive ART regimen for at least 24 months with no changes in the 90 days prior to study entry

• CD4+ cell count greater than 200 cells/mm3 obtained within 56 days prior to study entry

• HIV-1 RNA \<200 copies/mL obtained within 56 days prior to study entry

• Plasma HIV-1 RNA levels \<200 copies/mL for at least 12 months on ART prior to study entry

• The following laboratory values obtained within 56 days prior to study entry

‣ White blood cell count ≥2,500 cells/mm3

⁃ Absolute neutrophil count (ANC) \>750/mm3

⁃ Hemoglobin ≥11 g/dL for cisgender men/transgender women and ≥10 g/dL for cisgender women/transgender men

⁃ Platelet count ≥100,000/mm3

⁃ Creatinine \<1.5x upper limit of normal (ULN)

⁃ Alanine aminotransferase (ALT) (SGPT) ≤1.5 ULN

• Hepatitis C Virus (HCV) antibody-negative or HCV RNA negative result if indicated, within 56 days prior to study entry

• Negative hepatitis B surface antigen (HBsAg) result obtained within 56 days prior to study entry

• For study candidates of child-bearing potential, negative serum or urine pregnancy test at screening and within 48 hours prior to study entry

• No participation in conception process and agree to use at least one reliable form of contraception if participating in sexual activity that could lead to pregnancy during the study and for 8 weeks following the final study vaccine